In silico identification and in vitro and in vivo validation of anti-psychotic drug fluspirilene as a potential CDK2 inhibitor and a candidate anti-cancer drug

PLoS ONE

Volumn 10, Issue 7, 2015, Pages

  Shi, Xi Nan ^a,c   Li, Hongjian ^b   Yao, Hong ^b,e   Liu, Xu ^a   Li, Ling ^a   Leung, Kwong Sak ^b   Kung, Hsiangfu ^a,b   Lu, Di ^a   Wong, Man Hon ^d   Lin, Marie Chia Mi ^a,d  

^a KUNMING MEDICAL UNIVERSITY   (China)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c Department of Medicine Southwest Guizhou Vocational and Technical College for Nationalities ^*  (China)

^d Shenzhen University   (China)

^e XUZHOU MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AZELASTINE; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 2 INHIBITOR; CYCLIN E; ESTRADIOL BENZOATE; FLUOROURACIL; FLUSPIRILENE; LATADU; LS 194959; NANDROLONE PHENPROPIONATE; NILOTINIB; PALIPERIDONE; RETINOBLASTOMA PROTEIN; UNCLASSIFIED DRUG; VILAZODONE; CDK2 PROTEIN, HUMAN; NEUROLEPTIC AGENT; TUMOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CELL CYCLE G1 PHASE; COMPUTER MODEL; COMPUTER PROGRAM; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG IDENTIFICATION; DRUG PROTEIN BINDING; DRUG STRUCTURE; ENZYME PHOSPHORYLATION; FEMALE; HEPATOCELLULAR CARCINOMA CELL LINE; HEPG2 CELL LINE; HUH7 CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MOLECULAR DOCKING; MOUSE; NONHUMAN; STRUCTURE ANALYSIS; TUMOR XENOGRAFT; VALIDATION STUDY; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; CARCINOMA, HEPATOCELLULAR; CELL CYCLE S PHASE; COMPUTER SIMULATION; DRUG EFFECTS; DRUG SCREENING; ENZYMOLOGY; HEP-G2 CELL LINE; LIVER NEOPLASMS; METABOLISM; NUDE MOUSE; PATHOLOGY;

MUS MUSCULUS;

ANIMALS; ANTIPSYCHOTIC AGENTS; CARCINOMA, HEPATOCELLULAR; COMPUTER SIMULATION; CYCLIN-DEPENDENT KINASE 2; FEMALE; FLUSPIRILENE; G1 PHASE; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; MOLECULAR DOCKING SIMULATION; NEOPLASM PROTEINS; S PHASE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84940062416     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0132072     Document Type: Article

References (31)

1. Mariaule G, Belmont P. Cyclin-Dependent Kinase Inhibitors as Marketed Anticancer Drugs: Where Are We Now? A Short Survey. Molecules. 2014;19(9):14366-14382. doi: 10.3390/molecules190914366 PMID: 25215591
2. Senderowicz AM. Flavopiridol: the First Cyclin-Dependent Kinase Inhibitor in Human Clinical Trials. Investigational New Drugs. 1999;17(3):313-320. doi: 10.1023/A:1006353008903 PMID: 10665481
3. Azevedo WFD, Leclerc S, Meijer L, Havlicek L, Strnad M, Kim SH. Inhibition of Cyclin-Dependent Kinases by Purine Analogues. European Journal of Biochemistry. 1997;243(1-2):518-526. doi: 10. 1111/j.1432-1033.1997.0518a.x PMID: 9030780
4. Glab N, Labidi B, Qin LX, Trehin C, Bergounioux C, Meijer L. Olomoucine, an inhibitor of the cdc2/cdk2 kinases activity, blocks plant cells at the G1 to S and G2 to M cell cycle transitions. FEBS Letters. 1994;353(2):207-211. doi: 10.1016/0014-5793 (94) 01035-8 PMID: 7523194
5. Li H, Leung KS, Wong MH. idock: A multithreaded virtual screening tool for flexible ligand docking. In: Proceedings of the 2012 IEEE Symposium on Computational Intelligence in Bioinformatics and Computational Biology (CIBCB); 2012. p. 77-84.
6. Li H, Leung KS, Ballester PJ, Wong MH. istar: A Web Platform for Large-Scale Protein-Ligand Docking. PLoS ONE. 2014;9(1):e85678. doi: 10.1371/journal.pone.0085678 PMID: 24475049
7. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, et al. The Protein Data Bank. Nucleic Acids Research. 2000;28(1):235-242. doi: 10.1093/nar/28.1.235 PMID: 10592235
8. Berman H, Henrick K, Nakamura H. Announcing the worldwide Protein Data Bank. Nature Structural & Molecular Biology. 2003;10(12):980-980. doi: 10.1038/nsb1203-980
9. Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, et al. AutoDock4 and Auto-DockTools4: Automated docking with selective receptor flexibility. Journal of Computational Chemistry. 2009;30(16):2785-2791. doi: 10.1002/jcc.21256 PMID: 19399780
10. Irwin JJ, Shoichet BK. ZINC - A Free Database of Commercially Available Compounds for Virtual Screening. Journal of Chemical Information and Modeling. 2005;45(1):177-182. doi: 10.1021/ci049714 PMID: 15667143
11. Irwin JJ, Sterling T, Mysinger MM, Bolstad ES, Coleman RG. ZINC: A Free Tool to Discover Chemistry for Biology. Journal of Chemical Information and Modeling. 2012;52(7):1757-1768. doi: 10.1021/ci3001277 PMID: 22587354
12. Law V, Knox C, Djoumbou Y, Jewison T, Guo AC, Liu Y, et al. DrugBank 4.0: shedding new light on drug metabolism. Nucleic Acids Research. 2014;42(D1):D1091-D1097. doi: 10.1093/nar/gkt1068 PMID: 24203711
13. Huang SY, Zou X. Ensemble docking of multiple protein structures: Considering protein structural variations in molecular docking. Proteins: Structure, Function, and Bioinformatics. 2007;66(2):399-421. doi: 10.1002/prot.21214
14. Craig IR, Essex JW, Spiegel K. Ensemble Docking into Multiple Crystallographically Derived Protein Structures: An Evaluation Based on the Statistical Analysis of Enrichments. Journal of Chemical Information and Modeling. 2010;50(4):511-524. doi: 10.1021/ci900407c PMID: 20222690
15. Korb O, Olsson TSG, Bowden SJ, Hall RJ, Verdonk ML, Liebeschuetz JW, et al. Potential and Limitations of Ensemble Docking. Journal of Chemical Information and Modeling. 2012;52(5):1262-1274. doi: 10.1021/ci2005934 PMID: 22482774
16. Li H, Leung KS, Nakane T, Wong MH. iview: an interactive WebGL visualizer for protein-ligand complex. BMC Bioinformatics. 2014;15(1):56. doi: 10.1186/1471-2105-15-56 PMID: 24564583
17. Pines J. Four-dimensional control of the cell cycle. Nature Cell Biology. 1999;1(3):E73-E79. doi: 10. 1038/11041 PMID: 10559915
18. Cobrinik D. Pocket proteins and cell cycle control. Oncogene. 2005;24(17):2796-2809. doi: 10.1038/sj.onc.1208619 PMID: 15838516
19. Meraldi P, Lukas J, Fry AM, Bartek J, Nigg EA. Centrosome duplication in mammalian somatic cells requires E2F and Cdk2-Cyclin A. Nature Cell Biology. 1999;1(2):88-93. doi: 10.1038/10054 PMID: 10559879
20. Ma DL, Chan DSH, Leung CH. Drug repositioning by structure-based virtual screening. Chemical Society Reviews. 2013;42(5):2130-2141. doi: 10.1039/c2cs35357a PMID: 23288298
21. Khedr MA, Shehata TM, Mohamed ME. Repositioning of 2, 4-Dichlorophenoxy acetic acid as a potential anti-inflammatory agent: In Silico and Pharmaceutical Formulation study. European Journal of Pharmaceutical Sciences. 2014;65(0):130-138. doi: 10.1016/j.ejps.2014.09.014 PMID: 25245006
22. Zhong HJ, Liu LJ, Chan DSH, Wang HM, Chan PWH, Ma DL, et al. Structure-based repurposing of FDA-approved drugs as inhibitors of NEDD8-activating enzyme. Biochimie. 2014;102(0):211-215. doi: 10.1016/j.biochi.2014.03.005 PMID: 24657219
23. Teo CY, Rahman MBA, Chor ALT, Salleh AB, Ballester PJ, Tejo BA. Ligand-Based Virtual Screening for the Discovery of Inhibitors for Protein Arginine Deiminase Type 4 (PAD4). Metabolomics. 2013;3(1):118.
24. Ballester PJ, Richards WG. Ultrafast shape recognition to search compound databases for similar molecular shapes. Journal of Computational Chemistry. 2007;28(10):1711-1723. doi: 10.1002/jcc. 20681 PMID: 17342716
25. Trott O, Olson AJ. AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. Journal of Computational Chemistry. 2010;31(2):455-461. doi: 10.1002/jcc.21334 PMID: 19499576
26. Huang R, Southall N, Wang Y, Yasgar A, Shinn P, Jadhav A, et al. The NCGC Pharmaceutical Collection: A Comprehensive Resource of Clinically Approved Drugs Enabling Repurposing and Chemical Genomics. Science Translational Medicine. 2011;3(80):80ps16-80ps16. doi: 10.1126/scitranslmed. 3001862 PMID: 21525397
27. Kanehisa M, Goto S, Sato Y, Kawashima M, Furumichi M, Tanabe M. Data, information, knowledge and principle: back to metabolism in KEGG. Nucleic Acids Research. 2014;42(D1):D199-D205. doi: 10.1093/nar/gkt1076 PMID: 24214961
28. Pihan E, Colliandre L, Guichou JF, Douguet D. e-Drug3D: 3D structure collections dedicated to drug repurposing and fragment-based drug design. Bioinformatics. 2012;28(11):1540-1541. doi: 10.1093/bioinformatics/bts186 PMID: 22539672
29. Patil SP, Pacitti MF, Gilroy KS, Ruggiero JC, Griffin JD, Butera JJ, et al. Identification of antipsychotic drug fluspirilene as a potential p53-MDM2 inhibitor: a combined computational and experimental study. Journal of Computer-Aided Molecular Design. 2015;29(2):155-163. doi: 10.1007/s10822-014-9811-6 PMID: 25377899
30. Heykants JPP. The excretion and metabolism of the long-acting neuroleptic drug fluspirilene in the rat. Life Sciences. 1969;8(19, Part 1):1029-1039. doi: 10.1016/0024-3205 (69) 90154-4 PMID: 5351017
31. Xian LIN R, Wei TUO C, Jun LÜ Q, ZHANG W, Qi WANG S. Inhibition of tumor growth and metastasis with antisense oligonucleotides (Cantide) targeting hTERT in an in situ human hepatocellular carcinoma model. Acta Pharmacologica Sinica. 2005;26(6):762-768. doi: 10.1111/j.1745-7254.2005. 00762.x